DFV890: a new oral NLRP3 inhibitor—tested in an early phase 2a randomised clinical trial in patients with COVID-19 pneumonia and impaired respiratory function
Authors:
Top Cited Papers
- 14 September 2022
- journal article
- research article
- Published by Springer Nature in Infection
- Vol. 51 (3) , 641-654
Abstract
Background Coronavirus-associated acute respiratory distress syndrome (CARDS) has limited effective therapy to date. NLRP3 inflammasome activation induced by SARS-CoV-2 in COVID-19 contributes to cytokine storm. Methods This randomised, multinational study enrolled hospitalised patients (18–80 years) with COVID-19-associated pneumonia and impaired respiratory function. Eligible patients were randomised (1:1) via Interactive Response Technology to DFV890 + standard-of-care (SoC) or SoC alone for 14 days. Primary endpoint was APACHE II score at Day 14 or on day-of-discharge (whichever-came-first) with worst-case imputation for death. Other key assessments included clinical status, CRP levels, SARS-CoV-2 detection, other inflammatory markers, in-hospital outcomes, and safety. Findings Between May 27, 2020 and December 24, 2020, 143 patients (31 clinical sites, 12 countries) were randomly assigned to DFV890 + SoC (n = 71) or SoC alone (n = 72). Primary endpoint to establish clinical efficacy of DFV890 vs. SoC, based on combined APACHE II score, was not met; LSM (SE), 8·7 (1.06) vs. 8·6 (1.05); p = 0.467. More patients treated with DFV890 vs. SoC showed ≥ 1-level improvement in clinical status (84.3% vs. 73.6% at Day 14), earlier clearance of SARS-CoV-2 (76.4% vs. 57.4% at Day 7), and mechanical ventilation-free survival (85.7% vs. 80.6% through Day 28), and there were fewer fatal events in DFV890 group (8.6% vs. 11.1% through Day 28). DFV890 was well tolerated with no unexpected safety signals. Interpretation DFV890 did not meet statistical significance for superiority vs. SoC in primary endpoint of combined APACHE II score at Day 14. However, early SARS-CoV-2 clearance, improved clinical status and in-hospital outcomes, and fewer fatal events occurred with DFV890 vs. SoC, and it may be considered as a protective therapy for CARDS. Trial registration ClinicalTrials.gov, NCT04382053.Keywords
Funding Information
- Novartis Pharma AG
This publication has 32 references indexed in Scilit:
- NLRP3 inflammasome activation contributes to the pathogenesis of rheumatoid arthritisClinical and Experimental Immunology, 2018
- NLRP3 inflammasome pathways in atherosclerosisAtherosclerosis, 2017
- Declaration of Helsinki. Ethical Principles for Medical Research Involving Human SubjectsJahrbuch für Wissenschaft und Ethik, 2014
- The role of the NLRP3 inflammasome in goutJournal of Inflammation Research, 2011
- Interleukin-1β Causes Acute Lung Injury via αvβ5 and αvβ6 Integrin–Dependent MechanismsCirculation Research, 2008
- Pulmonary Edema Fluid from Patients with Early Lung Injury Stimulates Fibroblast Proliferation through IL-1β-Induced IL-6 ExpressionThe Journal of Immunology, 2004
- Therapeutic management of extrahepatic manifestations in patients with chronic hepatitis C virus infectionRheumatology, 2003
- The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trialsThe Lancet, 2001
- APACHE II: a severity of disease classification system.1985
- APACHE IICritical Care Medicine, 1985